US · Healthcare · Drug Manufacturers - General
EPS came in at 2.79 against a street estimate of 2.60 — a beat of 7.3%.
Analysts rate AstraZeneca PLC a buy (9 buy, 2 hold, 1 sell out of 12) with an average price target of $206.66.
CONFIDENT AstraZeneca reported strong underlying growth, positive pipeline momentum and reiterated full-year guidance, while restructuring and loss-of-exclusivity pressures remain key risks. Q3 FY26 China growth remained pressured by volume-based procurement, but management reported 13% growth excluding that impact. Analysts focused on restructuring, pipeline value, Tagrisso’s outlook, launch contribution, China and future R&D spending. Management emphasized reinvestment, pipeline breadth and continued commercial momentum. 2026-10-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| Investors Finance Co PLC | 3.33% |
| Vanguard Capital Management, LLC | 2.93% |
| Capital Research & Mgmt Co - Division 3 | 2.23% |
| NORGES BANK | 2.18% |
| Capital World Investors | 1.94% |
| FMR Inc | 1.86% |
| Wellington Management Company LLP | 1.84% |
| Legal & General Group PLC | 1.66% |
| Document | Date |
|---|---|
| Admission of further securities to trading (6-K) · Q4 2026 HEADLINE NUMBERS • AstraZeneca issued and admitted 11,948 ordinary shares to trading on the London Stock Exchange. • Following admission, total shar | 2026-11-02 |
| Quarterly results (6-K) · Q3 2026 HEADLINE NUMBERS • 9M 2026 total revenue was $46,881m, up 8% reported and 7% at constant exchange rates (CER). • Q3 2026 total revenue was $16,209m, | 2026-10-30 |
| Enhertu approved in eu for her2-positive ebc (6-K) · Q4 2026 HEADLINE NUMBERS • The European Commission approved Enhertu as an adjuvant treatment for adults with HER2-positive early breast cancer who have resid | 2026-10-27 |
| Ultomiris approved in us in igan (6-K) · Q4 2026 HEADLINE NUMBERS • AstraZeneca’s Ultomiris received accelerated US approval to reduce proteinuria in adults with primary immunoglobulin A nephropathy | 2026-10-22 |
| Astrazeneca completes equity investment in summit (6-K) · Q4 2026 HEADLINE NUMBERS • AstraZeneca completed a $2 billion equity investment in Summit Therapeutics on 5 October 2026. • The investment is intended to a | 2026-10-05 |
| Az & ds collaboration with summit for datroway (6-K) · Q4 2026 HEADLINE NUMBERS • On 02 October 2026, AstraZeneca and Daiichi Sankyo announced a clinical collaboration with Summit Therapeutics to evaluate Datrowa | 2026-10-02 |
| Admission of further securities to trading (6-K) · Q4 2026 HEADLINE NUMBERS • AstraZeneca issued and admitted 9,828 ordinary shares to trading. • Following admission, total shares outstanding increased to 1, | 2026-10-01 |
| Astrazeneca announces equity investment in summit (6-K) · Q3 2026 HEADLINE NUMBERS • AstraZeneca agreed to invest $2 billion in newly issued Summit Therapeutics equity. • The investment will give AstraZeneca rights | 2026-09-29 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $1.06 / share ex-date Aug 7, 2026 · pay Sep 8, 2026 | 2026-08-07 |
| Dividend | $2.17 / share ex-date Feb 20, 2026 · pay Mar 23, 2026 | 2026-02-20 |
| Split | 1 : 2 effective Feb 2, 2026 | 2026-02-02 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for AstraZeneca PLC — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.